Adalimumab (ADA) has been shown to be an effective treatment for Behçet's disease (BD)-related uveitis. We aimed at evaluating the cumulative retention rate of ADA during a 48-month follow-up period in patients with BD-related uveitis, the impact of a concomitant use of disease modifying anti-rheumatic drugs (DMARDs) on ADA retention rate, and differences according to the various lines of biologic therapy (ie, first- vs second-line or more). Predictive factors of response to ADA were also investigated.
Cumulative retention rate of adalimumab in patients with Behçet's disease-related uveitis: a four-year follow-up study / Fabiani, Claudia; Sota, Jurgen; Vitale, Antonio; Rigante, Donato; Emmi, Giacomo; Vannozzi, Lorenzo; Bacherini, Daniela; Lopalco, Giuseppe; Guerriero, Silvana; Gentileschi, Stefano; Capozzoli, Marco; Franceschini, Rossella; Frediani, Bruno; Galeazzi, Mauro; Iannone, Florenzo; Tosi, Gian Marco; Cantarini, Luca. - In: BRITISH JOURNAL OF OPHTHALMOLOGY. - ISSN 0007-1161. - ELETTRONICO. - (2017), pp. 310733-310733. [10.1136/bjophthalmol-2017-310733]
Cumulative retention rate of adalimumab in patients with Behçet's disease-related uveitis: a four-year follow-up study
Vitale, Antonio;Emmi, Giacomo;Vannozzi, Lorenzo;Bacherini, Daniela;
2017
Abstract
Adalimumab (ADA) has been shown to be an effective treatment for Behçet's disease (BD)-related uveitis. We aimed at evaluating the cumulative retention rate of ADA during a 48-month follow-up period in patients with BD-related uveitis, the impact of a concomitant use of disease modifying anti-rheumatic drugs (DMARDs) on ADA retention rate, and differences according to the various lines of biologic therapy (ie, first- vs second-line or more). Predictive factors of response to ADA were also investigated.
I documenti in FLORE sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
